NYSEAMERICAN:HEBHemispherx BioPharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Hemispherx BioPharma, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.52 -0.17 (-6.32 %) (As of 06/5/2020 04:00 PM ET) Add Compare Share Today's Range$2.45Now: $2.52▼$2.6150-Day Range N/A52-Week Range$1.69Now: $2.52▼$14.81Volume2.72 million shsAverage Volume102,599 shsMarket Capitalization$6.15 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingHemispherx BioPharma has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, Hemispherx BioPharma has a potential upside of 177.8% from its current price of $2.52.Amount of Analyst CoverageHemispherx BioPharma has received no research coverage in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesHemispherx BioPharma has received 202 “outperform” votes. (Add your “outperform” vote.)Underperform VotesHemispherx BioPharma has received 231 “underperform” votes. (Add your “underperform” vote.)Community SentimentHemispherx BioPharma has received 53.35% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Hemispherx BioPharma and other stocks. Vote “Outperform” if you believe HEB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HEB will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldHemispherx BioPharma does not currently pay a dividend.Dividend GrowthHemispherx BioPharma does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hemispherx BioPharma insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 3.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.11 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:HEB Previous SymbolNYSE:HEB CUSIPN/A CIK946644 Webwww.hemispherx.net Phone+1-407-2718516Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees31 Outstanding Shares2,442,000Market Cap$6.15 million Next Earnings DateN/A OptionableNot Optionable AMEX:HEB Rates by TradingView Receive HEB News and Ratings via Email Sign-up to receive the latest news and ratings for HEB and its competitors with MarketBeat's FREE daily newsletter. Hemispherx BioPharma (NYSEAMERICAN:HEB) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Hemispherx BioPharma? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hemispherx BioPharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Hemispherx BioPharma. How were Hemispherx BioPharma's earnings last quarter? Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) announced its quarterly earnings results on Thursday, August, 15th. The specialty pharmaceutical company reported ($1.07) earnings per share for the quarter, beating analysts' consensus estimates of ($1.70) by $0.63. The specialty pharmaceutical company earned $0.03 million during the quarter. View Hemispherx BioPharma's earnings history. When did Hemispherx BioPharma's stock split? How did Hemispherx BioPharma's stock split work? Shares of Hemispherx BioPharma reverse split on Tuesday, June 11th 2019. The 1-44 reverse split was announced on Friday, May 31st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 10th 2019. An investor that had 100 shares of Hemispherx BioPharma stock prior to the reverse split would have 2 shares after the split. What price target have analysts set for HEB? 2 brokers have issued 1 year price objectives for Hemispherx BioPharma's shares. Their forecasts range from $6.00 to $8.00. On average, they anticipate Hemispherx BioPharma's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 177.8% from the stock's current price. View analysts' price targets for Hemispherx BioPharma. Has Hemispherx BioPharma been receiving favorable news coverage? News headlines about HEB stock have trended negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Hemispherx BioPharma earned a news sentiment score of -2.7 on InfoTrie's scale. They also assigned news stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. View the latest news aboutHemispherx BioPharma. Who are some of Hemispherx BioPharma's key competitors? Some companies that are related to Hemispherx BioPharma include Exopharm (EX1), Skinbiotherapeutics (SBTX), ContraVir Pharmaceuticals (HEPA), BTC Health (BTC), Regeneus (RGS), Nyrada (NYR), C4X Discovery (C4XD), Cellmid (CDY), AorTech International (AOR), Prescient Therapeutics (PTX), Inhibitor Therapeutics (INTI), Destiny Pharma (DEST), Agronomics (ANIC), CAN-FITE BIOPHA/S (CANF) and Crescita Therapeutics (CTX). View all competitors. What other stocks do shareholders of Hemispherx BioPharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hemispherx BioPharma investors own include NewLink Genetics (NLNK), Biocept (BIOC), Goodrich Petroleum (GDPMQ), Inovio Pharmaceuticals (INO), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Palatin Technologies (PTN), Biopharmx (BPMX), CTI BioPharma (CTIC) and Novavax (NVAX). Who are Hemispherx BioPharma's key executives? Hemispherx BioPharma's management team includes the following people: Mr. Thomas K. Equels, Exec. Vice Chairman, CEO & Pres (Age 66)Mr. Adam Pascale, Chief Financial Officer (Age 71)Mr. Peter W. Rodino III, J.D., Exec. Director of Gov.al Relations, Gen. Counsel & Sec. (Age 68)Mr. Wayne S. Springate, Sr. VP of Operations (Age 48)Ms. Ellen Lintal, Chief Accounting Officer What is Hemispherx BioPharma's stock symbol? Hemispherx BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "HEB." How do I buy shares of Hemispherx BioPharma? Shares of HEB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Hemispherx BioPharma's stock price today? One share of HEB stock can currently be purchased for approximately $2.52. How big of a company is Hemispherx BioPharma? Hemispherx BioPharma has a market capitalization of $6.15 million. Hemispherx BioPharma employs 31 workers across the globe. What is Hemispherx BioPharma's official website? The official website for Hemispherx BioPharma is www.hemispherx.net. How can I contact Hemispherx BioPharma? Hemispherx BioPharma's mailing address is 860 N Orange Ave Ste B, ORLANDO, FL 32801-5205, United States. The specialty pharmaceutical company can be reached via phone at +1-407-2718516. This page was last updated on 6/6/2020 by MarketBeat.com Staff
